Telmisartan: Clinical Trials

61 trials of Telmisartan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

49 completed, 4 terminated, 4 unknown, 2 recruiting. 61 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 361Completed 49, Terminated 4, Unknown 4, Recruiting 2, Active not recruiting 1, Withdrawn 1
Phase 24Completed 3, Unknown 1

Follow Telmisartan: new trials by email Literature Review of Telmisartan trials Research Report on Telmisartan

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
Placebo, Telmisartan, Terazosin (Hytrin) - Parkinsons Disease (PD)
Phase 3RecruitingUniversity College, London12002025-09-122025-10-03
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
THP-00101, THP-00102, THP-00103 - Type 2 Diabetes, Hypertension
Phase 3Active not recruitingTHPharm Corp.2222025-04-102026-11-09
Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
Egito, Empagliflozin + telmisartan - Hypertension Associated, Type II Diabetes Mellitus
Phase 3WithdrawnEMS2023-08-012023-09-08
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg - Hypertension
Phase 3CompletedGeorge Medicines PTY Limited13852021-07-092025-06-03
Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo - Hypertension
Phase 3CompletedGeorge Medicines PTY Limited7552021-06-142025-06-03
Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection
Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol - Covid19, Covid19 Drug Treatment
Phase 2 / Phase 3UnknownANRS, Emerging Infectious Diseases6002021-04-122023-01-31
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment
Phase 2 / Phase 3CompletedANRS, Emerging Infectious Diseases2942020-11-272024-12-27
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
Losartan, Valsartan, Azilsartan - Covid19, SARS-CoV Infection
Phase 3TerminatedUniversity of British Columbia3412020-10-092023-02-16
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
Vitamins, Telmisartan, Ciclesonide - Corona Virus Infection, Sars-CoV2
Phase 2 / Phase 3CompletedUniversity Hospital, Bordeaux4122020-07-292026-05-12
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan - Primary Hypercholesterolemia, Hypertension
Phase 3UnknownHanlim Pharm. Co., Ltd.1562020-07-152020-12-09
Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19
Hydroxychloroquine, Azithromycin, Telmisartan - COVID-19 Infection
Phase 3TerminatedUniversity Hospital, Strasbourg, France162020-04-252022-07-11
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg, Placebo oral capsule - Cognitive Decline, Intracerebral Hemorrhage
Phase 3TerminatedThe George Institute12020-02-272021-04-01
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine
Ezetimibe/Rosuvastatin, Telmisartan, Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET - Hypercholesterolemia, Hypertension
Phase 3CompletedAddpharma Inc.1312020-01-232021-05-12
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
Ezetimibe/Rosuvastatin, Telmisartan - Hypercholesterolemia, Hypertension
Phase 3CompletedAddpharma Inc.1802019-02-262021-01-15
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial
telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, Placebo - Intracerebral Haemorrhage (ICH), Hypertension
Phase 3CompletedThe George Institute16712017-09-282025-09-12
Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia
Telmisartan + Amlodipine + Rosuvastatin, Telmisartan + Amlodipine, Telmisartan + Rosuvastatin - Hypertension, Dyslipidemia
Phase 3CompletedDaewon Pharmaceutical Co., Ltd.1292016-10-072018-02-01
Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin
Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg), Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo), Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg) - Dyslipidemia With Hypertension
Phase 3CompletedJeil Pharmaceutical Co., Ltd.1262016-09-202018-07-06
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide - Respiratory Tract Diseases, Influenza (Pandemic)
Phase 3RecruitingUMC Utrecht200002016-04-112026-11-04
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
telmisartan/amlodipine 40/5mg, YH22162 40/5/12.5 mg, telmisartan/amlodipine 80/5mg - Hypertension
Phase 3CompletedYuhan Corporation3812015-12-012024-11-12
Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia
Telmisartan/Amlodipine, Rosuvastatin, Telmisartan - Hypertension With Hyperlipidemia
Phase 3CompletedIlDong Pharmaceutical Co Ltd1342015-11-242018-06-25

Showing 20 of 61. Sign in to see all of them.

Conditions studied

Hypertension (45)  ·  COVID-19 (5)  ·  Diabetes Mellitus, Type 2 (3)  ·  Metabolic Syndrome (3)  ·  Cerebral Hemorrhage (2)  ·  Coronavirus Infections (2)  ·  Disease (2)  ·  Dyslipidemias (2)  ·  Essential Hypertension (2)  ·  Familial paroxysmal dystonia (2)  ·  Heart Diseases (2)  ·  Hypercholesterolemia (2)  ·  Hyperlipidemias (2)  ·  Polycystic Kidney Diseases (2)  ·  Polycystic Kidney, Autosomal Dominant (2)

Sponsors

Boehringer Ingelheim (27)  ·  IlDong Pharmaceutical Co Ltd (3)  ·  ANRS, Emerging Infectious Diseases (2)  ·  Addpharma Inc. (2)  ·  George Medicines PTY Limited (2)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2)  ·  The George Institute (2)  ·  Yuhan Corporation (2)  ·  Chong Kun Dang Pharmaceutical (1)  ·  Daewon Pharmaceutical Co., Ltd. (1)  ·  EMS (1)  ·  Hamilton Health Sciences Corporation (1)  ·  Hanlim Pharm. Co., Ltd. (1)  ·  Heidelberg University (1)  ·  Jeil Pharmaceutical Co., Ltd. (1)

Countries

South Korea (16)  ·  France (9)  ·  United States (8)  ·  Japan (7)  ·  Netherlands (7)  ·  Canada (6)  ·  Germany (6)  ·  United Kingdom (6)  ·  Australia (5)  ·  Czechia (5)  ·  Sweden (5)  ·  Taiwan (5)  ·  Finland (4)  ·  Italy (4)  ·  South Africa (4)

Top investigators

Anthony Rodgers, Professor (2)  ·  Arlene Chapman, M.D. (2)  ·  Hyo Soo Kim, M.D., Ph.D (2)  ·  Marva Moxey-Mims, M.D. (2)  ·  Robert Schrier, M.D. (2)  ·  Ronald Perrone, M.D. (2)  ·  Vicente Torres, M.D. (2)  ·  Arya M Sharma, MD, FRCPC (1)  ·  Charity G Moore, MS,PhD (1)  ·  Charity G Moore, PhD (1)  ·  Colin McArthur, Dr (1)  ·  Craig Anderson (1)

Results publications

PMID 34473343, PMID 39356039, PMID 14630977, PMID 14744931, PMID 15253732, PMID 15647341, PMID 15772249, PMID 16093916, PMID 19191674, PMID 22090469, PMID 22205355, PMID 23731019, PMID 23810874, PMID 24653513, PMID 25111236, PMID 25399731, PMID 25399733, PMID 29248384, PMID 29673890, PMID 30665829, PMID 30803434, PMID 30904178, PMID 32267771, PMID 32876697, PMID 33050924, PMID 33394942, PMID 33509275, PMID 33631065, PMID 34022170, PMID 34251506, PMID 34351721, PMID 34351722, PMID 34606578, PMID 34994269, PMID 35315874, PMID 36525245, PMID 36574985, PMID 36918388, PMID 36942550, PMID 36967714, PMID 37039790, PMID 37119829, PMID 37250503, PMID 37256341, PMID 37489818, PMID 37877585, PMID 37888913, PMID 38454482, PMID 38682786, PMID 39217570

NIH funding

2008 (2), U01DK062401 (2), U01DK082230 (2), 2015 (1), 2023 (1)